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Abstract 
Background: To reduce the risk of thromboembolic complications, clinical guidelines recommend anticoagulation 
treatment for almost all atrial fibrillation (AF) patients. Although warfarin has long been the primary treatment alterna-
tive, now newer alternatives such as apixaban have proven effective in prevention of the thromboembolic complica-
tions of non-valvular AF. The aim of this study is to assess the cost–effectiveness of apixaban when compared with 
warfarin in the prevention of AF-associated thromboembolic complications in Finland.
Methods: The assessment was performed with a lifetime Markov-model with the following health states: non-valvu-
lar AF, ischemic stroke, hemorrhagic stroke, other intracranial bleed, other major bleed, clinically relevant non-major 
bleed, myocardial infarction, and systemic embolism. The treatment efficacies were obtained from the ARISTOTLE trial. 
Representative Finnish input data were used for the model states, including background mortality, resource use, costs 
(in 2014 values), and EQ-5D-3L-based quality of life. The results (with 3 % annual discounting) are presented as incre-
mental cost–effectiveness ratios [ICER, cost per quality-adjusted life year (QALY) gained], the expected value of perfect 
information (EVPI), and the probability of apixaban being cost–effective at various willingness-to-pay levels.
Results: Apixaban increased life-expectancy by 0.17 years and quality-adjusted life-expectancy by 0.14 QALYs when 
compared with warfarin. Additional QALY was gained with apixaban at a cost of 1824 euros based on the determinis-
tic analysis. The maximum EVPI was 649 euros/patient at 1282 euros per QALY gained in the probabilistic analysis. The 
probability of apixaban being cost–effective reached 80 % when the willingness-to-pay per QALY gained was 14,857 
euros. In deterministic sensitivity analyses, ICERs varied from dominance of apixaban to additional QALY being gained 
at a cost of 12,312 euros.
Conclusions: The ICERs obtained were well below the WHO-CHOICE threshold values for cost–effective interven-
tions, suggesting that apixaban is a very cost–effective treatment alternative for warfarin in Finnish patients with AF.
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Background
Atrial fibrillation (AF) is a major risk factor for stroke, 
increasing the risk of stroke approximately fivefold (Wolf 
et al. 1991). In Finland, approximately 13 % of all patients 
with ischemic stroke have a prior diagnosis of AF (Mere-
toja et al. 2011). Warfarin has long been the recommended 
antithrombotic treatment for AF patients as it reduces the 
risk of stroke by approximately 60  % (Hart et  al. 2007). 
However, characteristics of warfarin including frequent 
monitoring of international normalized ratio (INR) and 
numerous drug interactions limit its use. Recent Finn-
ish studies suggest that warfarin is underused among AF 
patients. Approximately 50 % of all AF patients for whom 
anticoagulation is recommended in the Finnish Cur-
rent Care Guideline (2015) based on their stroke risk (i.e. 
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CHA2DS2-VASc ≥ 1, see e.g. Lip et al. 2010) were treated 
with warfarin in one municipality (Hallinen et al. 2014) and 
30 % of the previously diagnosed AF patients admitted to 
Finnish emergency departments due to AF did not receive 
warfarin treatment at the time of hospitalization despite 
their moderate to high risk of stroke (Lehto et al. 2011).
New anticoagulant treatments such as apixaban, dabi-
gatran, and rivaroxaban have all proven effective in the pre-
vention of thromboembolic complications in patients with 
non-valvular AF (Granger et al. 2011; Connolly et al. 2009; 
Patel et al. 2011). In Finland and many other countries the 
decision on whether to publicly fund the use of these drugs 
is at least partially based on the cost–effectiveness of the 
drug against the most-used treatment. In Finland, the costs 
of these new anticoagulants are currently reimbursed (35 % 
of costs are covered by the Social Insurance Institution) 
for patients with high risk of embolism (i.e. CHA2DS2-
VASc ≥  2) and patients with moderate risk of embolism 
(i.e. CHA2DS2-VASc =  1) when warfarin cannot be used 
due to its side-effects or interactions or when patients’ INR-
values during stabilized warfarin treatment remain in the 
target range less than 70 % of the time (Kela 2015).
The aim of this study was to assess the cost–effective-
ness of apixaban when compared with warfarin in the 
prevention of thromboembolic complications in Finnish 
AF patients. The study applies previously unpublished 
health care costs and quality of life estimates that have 
been observed for Finnish patients in real-life setting.
Results
Apixaban use increased life-expectancy and qual-
ity adjusted life-expectancy on average by 0.17 and 
0.14  years, respectively, when compared with warfarin 
(see Table 1). These gains were reached at an additional 
cost of 261 euros during patient’s life-time. An additional 
quality-adjusted life year (QALY) was therefore gained 
at a cost of 1824 euros, which is clearly below the com-
monly used threshold values for incremental cost–effec-
tiveness ratios (ICERs) that are considered to support 
claims of cost–effectiveness. The cost–effectiveness plane 
illustrating differences in costs and effects between apixa-
ban and warfarin is shown in Fig. 1.  
The cost–effectiveness acceptability frontier (CEAF) 
in Fig. 2 shows the probability of the optimal treatment 
being the most cost–effective treatment alternative at 
various willingness to pay (WTP) thresholds per QALY 
gained. The probability of apixaban being cost–effec-
tive reached 80  % when the WTP per QALY gained 
was 14,857 euros. Apixaban had 91 and 94  % probabil-
ity for cost–effectiveness when the WTP was 37,576 and 
112,728 euros per QALY gained, respectively. Based on 
the probabilistic simulation results and Bayesian treat-
ment ranking, apixaban had 95 % probability of being the 
first best option in terms of highest QALYs and had 45 % 
probability for the lowest costs.
As can be seen from Fig.  2, expected value of perfect 
information (EVPI) reached its maximum value of 649 
(2.5–97.5  % percentile 0–3409) euros per patient when 
the probabilistic ICER was 1282 euros per QALY gained. 
The EVPI was 166 (0–2556) and 234 (0–3474) euros per 
patient when WTP was 37,576 and 112,728 euros per 
QALY gained, respectively.
In deterministic sensitivity analyses ICERs varied 
between negative values, i.e. apixaban dominated war-
farin, and 12,312 euros per QALY gained. The highest 
ICERs were obtained in scenarios where apixaban was 
Table 1 Results of the cost–effectiveness analyses
Lifetime costs (€) Lifetime QALYs ICER (€/QALY gained)
Apixaban Warfarin Diff. Apixaban Warfarin Diff.
Base case 16,197 15,936 261 7.19 7.05 0.14 1824
Without discounting 20,647 20,442 205 8.99 8.80 0.19 1060
Sensitivity analyses
CHADS 0–1 15,491 14,931 560 7.25 7.12 0.13 4347
CHADS 2 16,151 15,708 443 7.20 7.07 0.13 3387
CHADS 3–6 17,012 17,266 −254 7.13 6.96 0.17 Dominant
TTR < 52.38 % 16,047 17,150 −1104 7.19 6.97 0.22 Dominant
52.38 % ≤ TTR < 66.02 % 17,397 16,170 1226 7.14 7.04 0.10 12,312
66.02 % ≤ TTR < 76.51 % 16,164 15,131 1033 7.20 7.10 0.10 10,386
TTR ≥ 76.51 % 15,150 15,249 −98.23 7.25 7.10 0.15 Dominant
No treatment discontinuations after trial period 19,473 19,042 431 7.24 7.04 0.21 2102
Warfarin monitoring cost −50 % 16,197 14,650 1546 7.19 7.05 0.15 10,817
Warfarin monitoring cost +50 % 16,197 17,222 −1025 7.19 7.05 0.14 Dominant
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compared with warfarin treatment with intermediate 
percentage times spent in the therapeutic INR range 
(TTRs) and when the cost of monitoring for warfarin was 
reduced by 50 %. Even the highest ICERs obtained were 
well below the common official international and unof-
ficial Finnish cost–effectiveness thresholds of 30,000 and 
47,000 euros per QALY gained.
Discussion
Apixaban use increased average treatment costs, life-
expectancy, and quality-adjusted life-expectancy of AF 
patients when compared with warfarin. An additional 
QALY was gained with apixaban at a cost of 1824 euros. 
Based on WHO-CHOICE threshold values for cost–effec-
tiveness (WHO 2016), our analysis suggests that apixaban 
can be considered a very cost–effective treatment alterna-
tive to warfarin in Finland. Based on a recent systematic 
literature review of cost–effectiveness studies of the new 
oral anticoagulants, our finding is in line with published 
assessments from other countries (Kansal et al. 2013).
Based on the extensive sensitivity analyses and CEAF, 
the results obtained were relatively robust and the prob-
ability of apixaban being cost–effective was high. The 
expected value of obtaining additional information for 
uncertain probabilistic model parameters remained 
relatively low and was around 649 euros per patient at 
maximum. This finding suggests that further research to 
reduce the uncertainty would be worthwhile only if the 
costs associated with further research were less than 649 
euros per study participant.
Perhaps the most interesting practical finding of our 
study was the non-linearity of ICERs with regard to war-
farin treatment quality. ICERs were lowest when the TTR 
was at either the higher or lower end of the spectrum. 
The highest ICERs were observed for intermediate TTRs. 
Although the subgroups analyses of the ARISTOTLE 
trial were not powered to detect significant differences 
between warfarin and apixaban in these TTR subgroups, 
it seems possible that in centers with high TTR values 
the patients may have been at higher risk of bleeds when 
compared with centers with lower TTRs. Because apixa-
ban use is associated with a lower risk of bleeds when 
compared with warfarin, this observation could explain 
the improvement in the cost–effectiveness of apixaban as 
TTR with warfarin increases. Interestingly, a recent Finn-
ish study (Soini et al. 2013) observed a potential associa-
tion between higher TTR and lower quality of life (QoL), 
perhaps reflecting a similar phenomenon.
On a broader perspective our assessment shows that 
QALYs gained during anticoagulation treatment are asso-
ciated with reasonable costs in relation to benefits gained 
regardless of whether the patients are treated with apixa-
ban or warfarin. In fact, our analysis illustrates a rare 
case (see Soini et  al. 2012) in which the ICER between 
compared treatments is very similar to the average cost–
effectiveness ratios (CER, i.e. cost/QALY for each com-
parator) for apixaban (2253 euros) and warfarin (2260 
euros). Based on the Bayesian treatment ranking of low-
est CER, the probability of being the first best option was 
53 % for apixaban and 47 % for warfarin. Even though the 
CERs implicitly reflect a comparison setting in which the 
comparator to given treatment would be “instant death” 
without any costs or QALYs (Soini et al. 2012), very high 
CERs may indicate that the treatment would not be con-
sidered acceptable from cost perspective (an exception 
to this interpretation would be the case in which the 
choice to “do nothing” or sc. “instant death” would lead to 
higher CER). In our study, this is clearly not an issue for 
either treatment. In the absence of common comparator, 
relative benefit of apixaban and warfarin versus the com-
mon comparator (e.g. placebo) could not be estimated 
and, thus, relative benefit–CER (see Soini et al. 2016) or 
ICERs in terms of given treatment versus the common 
Fig. 1 The cost-effectiveness plane for apixaban versus warfarin. 
Green line depicts ICER threshold equal to the Finnish GDP and red 
line depicts ICER threshold equal to 3 times the Finnish GDP 
Fig. 2 Cost-effectiveness acceptability frontier (CEAF) and expected 
value of information (EVPI) curves for the analysis. WTP=willingness 
to pay
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comparator were not implemented in this study. In fact, 
because warfarin was the recommended treatment prac-
tice at the time of ARISTOTLE trial, a placebo-controlled 
trial would have been unethical.
Our study has some important strengths. We collected 
both the cost and QoL data from representative Finnish 
data sources, thereby increasing the validity of our results 
in the Finnish context. Furthermore, the patient charac-
teristics and risk factors in the ARISTOTLE trial have 
previously been found to be similar to those of Finnish 
patients with atrial fibrillation (Hallinen et al. 2014). Our 
study also broadens the available information regarding 
the impact of stroke severity on patients’ QoL and costs. 
To our knowledge, such data or results have not been 
published previously. Lastly, we presented the probabilis-
tic results in terms of CEAF and EVPI.
There are always some limitations in cost–effectiveness 
assessments of chronic long-term illnesses that are based 
on modeling. AF is an especially complex disorder that 
has an impact on many health-related outcomes. Some 
aspects of the model used for this assessment can be 
considered conservative. An example of such an assump-
tion is the modeling of most events as absorbing states. 
This assumption means that after experiencing an event 
the patients were no longer at risk of other costly events. 
Such an assumption tends to favor the treatment that has 
proven less effective.
There is also some uncertainty regarding the potential 
QoL loss and costs associated with warfarin monitoring. 
A recent Finnish study suggests that warfarin monitoring 
may result in some QoL loss (Soini et al. 2013), which was 
not accounted for in our analysis. Another recent study 
(Hallinen et al. 2014) shows that the Finnish national unit 
costs (Hujanen et al. 2008) used in this study for warfarin 
monitoring may not be generalizable across Finland and 
in fact may underestimate the true payer costs, at least 
for some municipalities. Since we excluded the possible 
QoL loss associated with warfarin, estimated warfarin 
treatment costs based on national unit costs, excluded 
potential benefits from the re-allocation of warfarin 
monitoring resources (i.e. the opportunity cost of labor 
needed in warfarin monitoring may be higher than its 
unit cost) for other purposes (Hallinen et  al. 2012a, b), 
and the results were observed to be sensitive to warfarin 
treatment costs, our cost–effectiveness estimates may be 
conservative, at least for some municipalities.
Conclusions
The ICERs obtained for apixaban were well below the 
WHO-CHOICE thresholds for cost–effective interven-
tions, indicating that apixaban is a very cost–effective 
treatment alternative for warfarin in Finnish patients 
with AF. Based on the sensitivity, cost–effectiveness 
acceptability frontier, and expected value of perfect 
information analyses, the results were relatively robust; 
apixaban had a high probability of cost–effectiveness and 
the value of additional information for the probabilistic 
model parameters was relatively low.
Methods
The cost–effectiveness assessment was performed 
using a life-time Markov health state transition model 
with 6-week cycles that extrapolate the trial findings 
to a longer term. Since the model structure has been 
previously described in detail by Dorian et  al. (2014), 
it is summarized only briefly here. The assessment 
was based on the efficacy and safety findings from the 
ARISTOTLE trial (Granger et  al. 2011) together with 
Finnish data for QoL, costs, and mortality. ARISTO-
TLE trial was a multicentre, randomized, double-blind 
trial, comparing apixaban (5 mg twice daily) with war-
farin (target international normalized ratio, 2.0–3.0) in 
18,201 patients with atrial fibrillation and at least one 
additional risk factor for stroke. Direct comparisons 
from randomized, double-blind trials are the favored 
data source for assessing health effects of compared 
treatments in Finland (Pharmaceuticals Pricing Board 
2015), and ARISTOTLE trial is the only published phase 
III trial comparing aprixaban and warfarin in AF. We 
used secondary analysis of ARISTOTLE to derive model 
inputs (Dorian et al. 2014).
The main outcome measure was ICER calculated as the 
quotient of the mean cost and effectiveness differences 
between apixaban and warfarin. Since there are no offi-
cial Finnish thresholds for cost–effectiveness (Soini et al. 
2015) available, we applied the WHO-CHOICE thresh-
olds in the assessment (WHO 2016). Accordingly, the 
intervention is considered very cost–effective, cost–effec-
tive or not cost–effective, when the ICER is below the 
gross domestic product (GDP) per capita (<37,576 euros/
QALY gained based on the Finnish GDP in 2014 accord-
ing to Official Statistics of Finland 2016), the ICER is 1–3 
times the GDP per capita (37,576–112,728 euros/QALY 
gained) or the ICER is higher than three times the GDP 
per capita (>112,728 euros/QALY gained), respectively. 
The WHO-CHOICE thresholds are surprisingly similar 
to the overall results of the eight patient groups in a Finn-
ish contingent valuation study, where also average WTP 
of 47,000 euros per QALY gained was observed for cor-
onary heart disease (Soini et al. 2012). The effectiveness 
was estimated on the basis of QALY. QALYs were based 
on the survival and QoL was measured using EQ-5D-3L. 
All costs and outcomes were discounted at an annual rate 
of 3 %.
A probabilistic sensitivity analysis (PSA) with 2000 
simulations was performed. In the PSA, the values of 
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key input parameters were varied based on their prob-
ability distributions. A cost–effectiveness plane based on 
the PSA was drawn to illustrate the observed differences 
in costs and effects between compared treatments. In 
addition, a CEAF was drawn to depict the probability of 
cost–effectiveness for optimal treatments (in terms of net 
monetary benefit obtained) at different values of WTP 
per QALY gained (Barton et al. 2008; Soini et al. 2011). 
Conditional Bayesian Treatment Ranking (BTR) has been 
recently proposed as an assessment method for treatment 
ranking in terms of the probabilities for the first highest, 
second highest etc. benefits and the first lowest, second 
lowest etc. ICER versus minimum treatment (Soini et al. 
2016). We used the BTR to define the probabilities for 
the first highest QALYs, lowest costs and lowest average 
cost–effectiveness ratios (CER). In addition, the EVPI was 
estimated to assess the value of obtaining more informa-
tion (Barton et  al. 2008) on probabilistic model param-
eters in order to reduce the uncertainty associated with 
the treatment decision. A high EVPI suggests that there 
is a need for additional information (i.e. the net monetary 
benefit gains from new research information may exceed 
the research costs) or that the opportunity cost should be 
considered in decision-making (Soini et al. 2011).
Model
A schematic presentation of the model used is presented 
in Fig.  3. The modeled cohort consists of male (64.7  %) 
and female (35.3 %) patients with non-valvular AF, aged 
70 years, and with an average CHADS2-score (see Gage 
et  al. 2001) of 2.1 (Dorian et  al. 2014), which is well in 
line with the Finnish values (see Hallinen et al. 2014). In 
the model the patients start anticoagulation treatment 
and are modeled to reside in the “atrial fibrillation” health 
state until they die or experience one of the following 
permanent health events: ischemic stroke (mild, moder-
ate, severe or fatal), hemorrhagic stroke (mild, moder-
ate, severe or fatal), systemic embolism, or myocardial 
infarction (MI); or one of the following transient mutu-
ally exclusive events: other intracranial bleed (ICB), other 
major bleeds (gastrointestinal bleeds or other bleeds), or 
clinically relevant non-major bleeds. After permanent 
events the patients are no longer at risk of other events 
apart from death. After transient events the patients 
recover their previous health states after one cycle. The 
event rates are summarized in Table 2.
Mortality is modeled separately for the above health 
events (Dorian et  al. 2014) and other causes. The other 
cause mortality is modeled on the basis of official Finn-
ish life tables by applying a weighted relative risk of 1.24 
for death due to AF as compared with the general Finn-
ish population. The applied increase in mortality risk 
was based on the finding that AF increases the mortal-
ity risk by approximately 1.5-fold in women and 1.1-fold 
in men (Benjamin et  al. 1998). Similarly, mortality is 
increased after stroke (both ischemic and hemorrhagic) 
and MI when compared with the general population. We 
derived the following standardized mortality ratios from 
the studies by Huybrechts et  al. (2008) and Brønnum-
Hansen et al. (2001): mild stroke 1.386, moderate stroke 
2.440, severe stroke 6.384, MI women 2.330, and MI men 
1.740. In addition, Finnish case fatality rates were applied 
for event rates that were not available from the ARISTO-
TLE trial. The case fatality rate for systemic embolism 
(10.5 %) was approximated from the Official Statistics of 
Finland (2010, 2011) and the case fatality rate for MIs was 
estimated from the Finnish National Cardiovascular Dis-
eases Register based on year 2012 (14.2  % for men and 
16.9  % for women). The Finnish 30  day-case fatality for 
MI among patients who make it to the hospital has been 
reported to be 13.5  % for men and 15.8  % for women 
(Häkkinen et  al. 2007), but these rates exclude patients 
who die before being hospitalized.
In the model, the patients may discontinue their antico-
agulation treatment due to modeled events or unrelated 
reasons after which they may switch to a second-line 
treatment [warfarin, acetylsalicylic acid (ASA)] or to no 
treatment. For simplicity we assumed that the patients 
would not receive further antithrombotic treatment after 
treatment discontinuance. Permanent treatment dis-
continuance was assumed for all hemorrhagic strokes 
whereas patients with other ICBs and other major bleeds 
were assumed to discontinue treatment either perma-
nently or temporarily for 6 weeks as described by Dorian 
et al. (2014).
The model allows the adjustment of stroke and bleed-
ing risks during warfarin treatment based on the TTR. 
The event rates for patients with different TTRs were Fig. 3 Schematic presentation of the cost-effectiveness model
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obtained from a secondary analysis of the ARISTO-
TLE trial data, in which the trial centers were classi-
fied into four groups of equal size (i.e. 25 % of the study 
centers belonged to each group) based on the center’s 
TTR (cTTR  <  52.38  %, 52.38  %  ≤  cTTR  <  66.02  %, 
66.02 % ≤ cTTR < 76.51 %, and cTTR ≥ 76.51 %) (Dorian 
et al. 2014). By varying the proportion of patients belong-
ing to each of these subgroups in the model, the impact 
of warfarin treatment quality on cost–effectiveness was 
assessed in a sensitivity analysis.
Quality of life (QoL) estimates
QoL associated with health states was estimated from a 
nationally representative sample of Finnish inhabitants 
who participated in the Health 2000 study (Methodology 
report, Health 2000 Survey 2008).
In the model, the patients’ disability status after stroke 
is based on the modified Ranking Scale (mRS), which was 
not assessed in the Health 2000 study as such. Instead, we 
classified patients into the mRS categories on the basis 
of their answers to the ‘mobility’ and ‘usual activities’ 
dimensions of the 15D health-related QoL questionnaire 
(Sintonen 2001) as follows: answers 1–2 to both 15D 
dimensions was considered a mild stroke; answers 3–4 to 
either dimension was considered a moderate stroke, and 
answer 5 to either dimension was considered a severe 
stroke.
The QoL impact of the studied conditions in the Health 
2000 study data was estimated using a regression method 
whereby the differences in utilities measured with EQ-
5D-3L was explained with the conditions of interest. Due 
to difficulties in defining appropriate diagnoses for clini-
cally relevant non-major bleeds and other major bleeds 
in the data set, the impact of these health events was 
not analyzed in the regression models. The QoL scores 
associated with health states are reported in Table 3. For 
probabilistic sensitivity analysis, the QoL values were 
modeled as beta distributions with large standard errors 
(20 % of the mean value).
Costs
Health care payer perspective was used in the analysis. 
Direct health care costs excluding value added tax were 
included as costs in the analysis. The costs were assessed 
at real values in 2014 euros.
The applied daily drug cost was 2.77 euros for apixa-
ban (5 mg twice daily) and 0.09 euros for warfarin (5 mg 
once daily). In addition, 1.67 and 1.80 % of the patients on 
Table 2 Risk of modeled health events according to treatment
a Other cause mortality after the trial period was estimated by fitting a Gompertz survival function to the Finnish life tables
b For reasons other than modeled events
c The relative risk estimates from the AVERROES trial (Connolly et al. 2011) were applied to the apixaban event rates in the ARISTOTLE trial (Granger et al. 2011)
1 Dorian et al. (2014)
2 The ASA event rates were transformed using a relative risk (RR) reduction of 0.19 (Lip and Lim 2007) for ASA versus placebo
3 The ASA event rates were transformed using RR = 0.72 (Yerman et al. 2007) for ASA versus placebo
4 An RR of 0.19 for stroke was assumed to apply for SE as well
ARISTOTLE
Rate per 100 patient years1
Second line treatment
Rate per 100 patient years
Apixaban Warfarin ASAc No antithrombotic treatment
Ischemic stroke by CHADS2-score
 0–1 (34 % of patients) 0.521 0.458
 2 (35.8 % of patients) 0.950 0.934
 3–6 (30.2 % of patients) 1.534 1.944
 Weighted average/average 0.981 1.021 2.280 2.812
Hemorrhagic stroke 0.254 0.512 0.388 –
Other intracranial bleed 0.076 0.288 1.455 –
Other major bleed: gastrointestinal 0.680 0.795 1.455 –
Other major bleed: not gastrointestinal 1.110 1.476 1.455 –
Clinically relevant non-major bleed 2.083 2.995 1.811 –
Myocardial infarction 0.530 0.610 0.616 0.8563
Systemic embolism 0.090 0.100 0.600 0.4864
Mortality for the trial durationa 3.0825 3.3404
Other cardiovascular hospitalizations – –
Treatment discontinuationb 13.177 14.405
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apixaban and warfarin, respectively, experienced dyspep-
sia during treatment in the ARISTOTLE trial. Dyspepsia 
was assumed to require one general physician (GP) visit, 
to last for 3 months, and to be treated with pantoprazole 
20 mg/day (19.54 euros/package for 3 month treatment). 
Routine follow-up of patients was assumed to consist 
of an annual GP visit (116.82€) and warfarin monitor-
ing (38.39€) was assumed to take place 17 times per year 
(Hallinen et  al. 2006). Similar monitoring frequencies 
have also been reported in other Finnish studies (Hal-
linen et al. 2014; Soini et al. 2013).
The cost estimates associated with health states 
(Table  3) were derived from the Finnish Hospital Dis-
charge Register (see e.g. Sund 2012), which covers the 
public specialized health care in Finland, and the national 
hospital benchmarking database (Linna and Häkkinen 
2008). First, all patients with a diagnosis of AF (WHO 
International Classification of Diseases 10 (ICD-10) code: 
I48, n =  30,680) were identified from the databases for 
2007. Then the costs of care for the acute events, total 
health care costs for three consecutive years (1 year prior 
and 2  years following the event), and the proportion of 
patients who died within 1  year of the event were col-
lected. Because the patients’ mRS were not available for 
cost estimation, we classified strokes as mild, moderate, 
or severe when the patient was discharged home, admit-
ted to a rehabilitative institution or institutional care 
following the acute event, respectively. Since the health 
care costs for the first year are typically high due to acute 
event costs, use of first-year costs would overestimate the 
costs in successive years. Therefore the annual mortal-
ity adjusted maintenance costs (in 2007 values) follow-
ing the events were estimated as follows: (1) the acute 
event cost were subtracted from the total costs for 2 years 
after the event to obtain 2-year maintenance costs; (2) 
annual maintenance costs were derived from 2-year 
maintenance costs by assuming that the costs during 
the first 2 years after events would be equal for patients 
who are alive at the start of each year [i.e. annual main-
tenance cost  =  2-year costs/(1  +  % of patients alive at 
the start of year 2)]; (3) the average health care costs for 
1 year prior to the index event were deducted from the 
annual maintenance costs to obtain an estimate of the 
additional health care costs following the index events. 
The costs were then inflated into 2014 values with a fac-
tor of 1.1998 (Official Statistics of Finland 2015) and into 
monthly costs by dividing them by 12.
Sensitivity analyses
In deterministic sensitivity analyses we tested the impact 
of the following changes to input variables: (a) vary-
ing CHADS2-scores, (b) varying TTR, (c) no treatment 
Table 3 Applied average Finnish health state costs (year 
2014 values) and quality of life values
a In the regression model the constant term was 1.068, the disutility associated 
with AF was −0.045, and the decrease in QoL per year of age was −0.004. As a 
result, the QoL in AF state equals 0.743 (=1.068 − 0.004 × 70 − 0.045, where 70 
is the average age of patients)
b Hallinen et al. (2006, 2012a, b)
c GP-visit at primary health care (Kapiainen et al. 2014)
d Disutility applied for 6 weeks
e Assumed to be equal to other intracranial bleeds. Disutility applied for 14 days
f Sullivan et al. (2011). Disutility applied for 2 days
Model state Cost, € EQ-5D-3L score (n = 5690)
Atrial fibrillation 0.743a
 Monitoring visit (warfarin only) 38.39b
 Routine care, GP visit 116.82c
Ischemic stroke
 Mild −0.087
  Acute Care, per episode 4429.23




  Acute Care, per episode 7526.19




  Acute Care, per episode 7532.07






  Acute Care, per episode 2628.91




  Acute Care, per episode 9218.05




  Acute Care, per episode 9399.58





  Acute Care, per episode 2072.39
  Long-term maintenance, per 
month
104.08
Other intracranial bleeds, per 
episode
4257.04 −0.168d
Other major bleeds −0.168e
GI bleeds, per episode 3448.80
Non-GI bleeds, per episode 3448.80
Clinically relevant non-major bleeds 2006.51 −0.0582f
Myocardial infarction −0.005
  Acute Care, per episode 5316.31
  Long-term maintenance, per 
month
525.00
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discontinuations after trial duration, and the cost of war-
farin monitoring (d) increased and (e) decreased by 50 %.
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